Clinical Trial
doi: 10.1016/j.eurpsy.2004.07.001.
Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia
Affiliations
- PMID: 15363480
- DOI: 10.1016/j.eurpsy.2004.07.001
Item in Clipboard
Clinical Trial
Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia
Eur Psychiatry.
2004 Sep.
No abstract available
Similar articles
-
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Hum Psychopharmacol. 2014 Jan;29(1):83-8. doi: 10.1002/hup.2376. Hum Psychopharmacol. 2014. PMID: 24424709 Clinical Trial.
-
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.J Clin Psychopharmacol. 1996 Feb;16(1):38-44. doi: 10.1097/00004714-199602000-00007. J Clin Psychopharmacol. 1996. PMID: 8834417 Clinical Trial.
-
Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.Pharmatherapeutica. 1989;5(5):285-91. Pharmatherapeutica. 1989. PMID: 2568639 Clinical Trial.
-
[Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].Neuropsychopharmacol Hung. 2012 Sep;14(3):189-95. Neuropsychopharmacol Hung. 2012. PMID: 22987732 Review. Hungarian.
-
Levomepromazine (methotrimeprazine) and the last 48 hours.Hosp Med. 1999 Aug;60(8):564-7. doi: 10.12968/hosp.1999.60.8.1175. Hosp Med. 1999. PMID: 10621810 Review.
Cited by
-
Antipsychotic combinations for schizophrenia.Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD009005. doi: 10.1002/14651858.CD009005.pub2. Cochrane Database Syst Rev. 2017. PMID: 28658515 Free PMC article.
-
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD009377. doi: 10.1002/14651858.CD009377.pub3. Cochrane Database Syst Rev. 2017. PMID: 28758203 Free PMC article.
-
Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacol Rep. 2025 Mar;45(1):e12497. doi: 10.1002/npr2.12497. Epub 2024 Nov 25. Neuropsychopharmacol Rep. 2025. PMID: 39587785 Free PMC article. No abstract available.
-
Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12. Neuropsychopharmacol Rep. 2021. PMID: 34390232 Free PMC article. No abstract available.
-
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Schizophr Bull. 2009 Mar;35(2):443-57. doi: 10.1093/schbul/sbn018. Epub 2008 Apr 15. Schizophr Bull. 2009. PMID: 18417466 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
